A Phase 2/3 interventional study of DRSP 3 mg/EE 20 µg (13 cycles) and DRSP 3 mg/EE 30 µg (6 cycles) in Dysmenorrhea, sponsored by Bayer. Completed at 26 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-01-24.
Sponsored by Bayer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dysmenorrhea by Bayer — none open to participants now, none under way, none of them phase 3. Dysmenorrhea · Bayer.
Among the 11 studies in Dysmenorrhea by Bayer, this one is one of 3 that started in 2007, is one of 2 in phase 2/3, and was the 1st registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →None of the 11 studies in Dysmenorrhea by Bayer is open now. The open studies under Dysmenorrhea, anywhere →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 223 across the 7 interventional studies, 658 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Dysmenorrhea by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate efficacy of ethinylestradiol for intracyclic bleeding profile in patients with dysmenorrhea and to investigate the long term safety
The "drospirenone 3 mg/ethinylestradiol 20 μg (13 cycles)" group is to be treated by oral administration for 52 weeks, 13 cycles. The "drospirenone 3 mg/ethinylestradiol 30 μg (6 cycles)" group is to be treated by oral administration for 24 weeks, 6 cycles.
The trial is sponsored by Bayer Yakuhin, Ltd.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
Drug: DRSP 3 mg/EE 20 µg (13 cycles)
1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Drug: DRSP 3 mg/EE 30 µg (6 cycles)
Drug page: Drospirenone
1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
Drug page: Drospirenone
1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Number of Participants With Intracyclic Bleeding at Cycle 6
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6
Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.
Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle
Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13
Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.
Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle
Distribution of Total Dysmenorrhea Score at Cycle 6
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Distribution of Total Dysmenorrhea Score at Cycle 13
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6
Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13
Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Distribution of Severity of Lumbago During Menstruation at Cycle 6
Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Distribution of Severity of Lumbago During Menstruation at Cycle 13
Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Distribution of Severity of Headache During Menstruation at Cycle 6
Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Distribution of Severity of Headache During Menstruation at Cycle 13
Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6
Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13
Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6
Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13
Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle
Number of Any Bleeding Episodes From Cycle 1 to Cycle 6
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Any Bleeding Episodes From Cycle 1 to Cycle 13
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Number of Any Bleeding Days From Cycle 1 to Cycle 6
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Any Bleeding Days From Cycle 1 to Cycle 13
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6
Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13
Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
Time frame: Up to Cycle 6 (168 days) with 28 days per cycle
Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
Time frame: Up to Cycle 13 (364 days) with 28 days per cycle
Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6
CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.
Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle
Change in Serum CA-125 From Baseline to Cycle 13
CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.
Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle
Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6
CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.
Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle
Change in Serum CRP From Baseline to Cycle 13
CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.
Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle
| Milestone | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Started | 355 | 65 |
| Subjects dispensed drugs | 350 | 65 |
| Subjects received treatment | 349 | 65 |
| Completed | 254 | 56 |
| Not completed | 101 | 9 |
| Withdrew: Adverse event | 26 | 3 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Protocol violation | 13 | 2 |
| Withdrew: Withdrawal by subject | 48 | 2 |
| Withdrew: Never dispensed | 5 | 0 |
| Withdrew: Study drug not taken | 1 | 0 |
| Withdrew: Partially missing diary | 2 | 0 |
| Withdrew: Other (missing drug etc) | 2 | 0 |
| Milestone | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Started | 349 | 0 |
| Completed | 254 | 0 |
| Not completed | 95 | 0 |
| Withdrew: Adverse event | 26 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Protocol violation | 13 | 0 |
| Withdrew: Withdrawal by subject | 48 | 0 |
| Withdrew: Partially missing diary | 2 | 0 |
| Withdrew: Other (missing drug etc) | 2 | 0 |
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Number of Participants With Intracyclic Bleeding at Cycle 6 | 40 | 4 |
Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| -6 (change in total dysmenorrhea scores) | 5 | 2 |
| -5 (change in total dysmenorrhea scores) | 22 | 3 |
| -4 (change in total dysmenorrhea scores) | 41 | 8 |
| -3 (change in total dysmenorrhea scores) | 70 | 13 |
| -2 (change in total dysmenorrhea scores) | 71 | 10 |
| -1 (change in total dysmenorrhea scores) | 30 | 12 |
| 0 (change in total dysmenorrhea scores) | 25 | 4 |
| 1 (change in total dysmenorrhea scores) | 4 | 2 |
| 2 (change in total dysmenorrhea scores) | 4 | 0 |
| 3 (change in total dysmenorrhea scores) | 0 | 0 |
| 4 (change in total dysmenorrhea scores) | 0 | 0 |
| 5 (change in total dysmenorrhea scores) | 0 | 0 |
| 6 (change in total dysmenorrhea scores) | 0 | 0 |
Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| -6 (change in total dysmenorrhea scores) | 4 |
| -5 (change in total dysmenorrhea scores) | 22 |
| -4 (change in total dysmenorrhea scores) | 47 |
| -3 (change in total dysmenorrhea scores) | 68 |
| -2 (change in total dysmenorrhea scores) | 44 |
| -1 (change in total dysmenorrhea scores) | 32 |
| 0 (change in total dysmenorrhea scores) | 12 |
| 1 (change in total dysmenorrhea scores) | 11 |
| 2 (change in total dysmenorrhea scores) | 2 |
| 3 (change in total dysmenorrhea scores) | 0 |
| 4 (change in total dysmenorrhea scores) | 0 |
| 5 (change in total dysmenorrhea scores) | 0 |
| 6 (change in total dysmenorrhea scores) | 0 |
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| 0 | 65 | 13 |
| 1 | 79 | 16 |
| 2 | 49 | 9 |
| 3 | 42 | 8 |
| 4 | 19 | 3 |
| 5 | 17 | 4 |
| 6 | 1 | 1 |
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| 0 | 73 |
| 1 | 66 |
| 2 | 41 |
| 3 | 24 |
| 4 | 24 |
| 5 | 13 |
| 6 | 1 |
Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| none | 75 | 14 |
| mild | 119 | 19 |
| moderate | 59 | 16 |
| severe | 19 | 5 |
Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| none | 78 |
| mild | 106 |
| moderate | 47 |
| severe | 11 |
Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| none | 154 | 21 |
| mild | 88 | 29 |
| moderate | 26 | 2 |
| severe | 4 | 2 |
Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| none | 148 |
| mild | 72 |
| moderate | 19 |
| severe | 3 |
Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| none | 187 | 37 |
| mild | 41 | 4 |
| moderate | 29 | 11 |
| severe | 15 | 2 |
Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| none | 168 |
| mild | 38 |
| moderate | 30 |
| severe | 6 |
Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| none | 251 | 51 |
| mild | 14 | 1 |
| moderate | 4 | 2 |
| severe | 3 | 0 |
Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| none | 229 |
| mild | 11 |
| moderate | 2 |
| severe | 0 |
Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| 0 | 202 | 34 |
| 1 | 52 | 13 |
| 2 | 11 | 4 |
| 3 | 2 | 1 |
| 4 | 2 | 1 |
| 5 | 2 | 0 |
| 6 | 0 | 1 |
Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| 0 | 177 |
| 1 | 49 |
| 2 | 12 |
| 3 | 2 |
| 4 | 2 |
| 5 | 0 |
| 6 | 0 |
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
| scores on a scale | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6 | -37.2 (-91 to 47) | -31.9 (-71 to 13) |
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
| scores on a scale | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13 | -41.6 (-91 to 36) |
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
| scores on a scale | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6 | 6.7 (0 to 80) | 12.2 (0 to 83) |
VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).
| scores on a scale | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13 | 6.2 (0 to 65) |
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).
| number of episodes | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Reference period 1 | 3.3 (1 to 7) | 3.4 (1 to 7) |
| Reference period 2 | 3.3 (0 to 10) | 3.1 (2 to 7) |
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).
| number of episodes | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Reference period 1 | 3.2 (1 to 7) |
| Reference period 2 | 3.5 (0 to 10) |
| Reference period 3 | 3.1 (0 to 8) |
| Reference period 4 | 3.2 (0 to 8) |
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).
| days | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Reference period 1 | 30.7 (14 to 65) | 28.9 (13 to 65) |
| Reference period 2 | 19.3 (0 to 78) | 19.9 (9 to 42) |
Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).
| days | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Reference period 1 | 30.6 (14 to 65) |
| Reference period 2 | 19.8 (0 to 79) |
| Reference period 3 | 21.2 (0 to 88) |
| Reference period 4 | 17.7 (0 to 69) |
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Cycle 1 | 94 | 19 |
| Cycle 2 | 38 | 8 |
| Cycle 3 | 45 | 8 |
| Cycle 4 | 33 | 3 |
| Cycle 5 | 40 | 5 |
| Cycle 6 | 29 | 4 |
Intracyclic bleedings were defined as bleedings while a participant takes active tablets.
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Cycle 1 | 93 |
| Cycle 2 | 38 |
| Cycle 3 | 45 |
| Cycle 4 | 33 |
| Cycle 5 | 41 |
| Cycle 6 | 40 |
| Cycle 7 | 114 |
| Cycle 8 | 24 |
| Cycle 9 | 24 |
| Cycle 10 | 24 |
| Cycle 11 | 21 |
| Cycle 12 | 23 |
| Cycle 13 | 31 |
Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.
| participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Cycle 1 | 276 | 54 |
| Cycle 2 | 310 | 57 |
| Cycle 3 | 302 | 58 |
| Cycle 4 | 290 | 54 |
| Cycle 5 | 279 | 54 |
| Cycle 6 | 185 | 52 |
Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.
| participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Cycle 1 | 274 |
| Cycle 2 | 314 |
| Cycle 3 | 307 |
| Cycle 4 | 295 |
| Cycle 5 | 289 |
| Cycle 6 | 285 |
| Cycle 7 | 229 |
| Cycle 8 | 259 |
| Cycle 9 | 245 |
| Cycle 10 | 250 |
| Cycle 11 | 246 |
| Cycle 12 | 243 |
| Cycle 13 | 241 |
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
| Percentage of participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Cycle 1 | 90.3 | 89.5 |
| Cycle 2 | 97.4 | 100.0 |
| Cycle 3 | 91.1 | 100.0 |
| Cycle 4 | 87.9 | 100.0 |
| Cycle 5 | 87.8 | 80.0 |
| Cycle 6 | 92.5 | 100.0 |
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
| Percentage of participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Cycle 1 | 90.3 |
| Cycle 2 | 97.4 |
| Cycle 3 | 91.1 |
| Cycle 4 | 87.9 |
| Cycle 5 | 87.8 |
| Cycle 6 | 92.5 |
| Cycle 7 | 90.4 |
| Cycle 8 | 100.0 |
| Cycle 9 | 87.5 |
| Cycle 10 | 100.0 |
| Cycle 11 | 100.0 |
| Cycle 12 | 100.0 |
| Cycle 13 | 90.3 |
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
| Percentage of participants | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Cycle 1 | 90.1 | 87.0 |
| Cycle 2 | 90.8 | 94.7 |
| Cycle 3 | 91.2 | 87.9 |
| Cycle 4 | 92.2 | 92.6 |
| Cycle 5 | 92.7 | 88.9 |
| Cycle 6 | 90.9 | 88.5 |
Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).
| Percentage of participants | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Cycle 1 | 90.1 |
| Cycle 2 | 90.8 |
| Cycle 3 | 91.2 |
| Cycle 4 | 92.2 |
| Cycle 5 | 92.7 |
| Cycle 6 | 90.9 |
| Cycle 7 | 91.3 |
| Cycle 8 | 91.1 |
| Cycle 9 | 91.0 |
| Cycle 10 | 90.8 |
| Cycle 11 | 91.9 |
| Cycle 12 | 93.8 |
| Cycle 13 | 93.8 |
CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.
| Units/mL | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6 | -4.33 (-134.8 to 46.1) | -5.50 (-102.6 to 3.2) |
CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.
| Units/mL | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Change in Serum CA-125 From Baseline to Cycle 13 | -4.66 (-135.5 to 90.0) |
CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.
| mg/dL | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6 | 0.159 (-0.83 to 7.98) | 0.000 (-1.62 to 1.37) |
CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.
| mg/dL | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| Change in Serum CRP From Baseline to Cycle 13 | 0.014 (-0.90 to 1.99) |
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| scores on a scale | DRSP 3 mg/EE 20 µg (6 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| age: < 30 years | -2.4 ± 1.68 | -2.2 ± 1.64 |
| age: >= 30 years | -2.2 ± 1.52 | -2.1 ± 1.69 |
| weight: < 50 kg | -2.0 ± 1.58 | -2.3 ± 1.76 |
| weight: >= 50kg | -2.5 ± 1.61 | -2.0 ± 1.60 |
| functional dysmenorrhea | -2.4 ± 1.64 | -2.3 ± 1.54 |
| organic dysmenorrhea | -2.0 ± 1.45 | -1.3 ± 1.91 |
| with medical surgical history | -2.3 ± 1.61 | -2.0 ± 1.69 |
| without medical surgical history | -2.4 ± 1.54 | -2.4 ± 1.60 |
| with previous medication | -2.3 ± 1.61 | -2.1 ± 1.66 |
| with pregnancy history | -2.2 ± 1.67 | -2.1 ± 1.68 |
| with birth history | -2.0 ± 1.71 | -2.4 ± 1.83 |
| total dysmenorrhea score at baseline 3/4 | -1.9 ± 1.37 | -1.9 ± 1.37 |
| total dysmenorrhea score at baseline 5/6 | -3.0 ± 1.73 | -2.6 ± 2.04 |
Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.
| scores on a scale | DRSP 3 mg/EE 20 µg (13 Cycles) |
|---|---|
| age: < 30 years | -2.5 ± 1.67 |
| age: >= 30 years | -2.4 ± 1.70 |
| weight: < 50 kg | -2.1 ± 1.68 |
| weight: >= 50kg | -2.7 ± 1.65 |
| functional dysmenorrhea | -2.6 ± 1.70 |
| organic dysmenorrhea | -2.1 ± 1.59 |
| with medical surgical history | -2.5 ± 1.72 |
| without medical surgical history | -2.5 ± 1.64 |
| with previous medication | -2.5 ± 1.69 |
| with pregnancy history | -2.1 ± 1.75 |
| with birth history | -1.9 ± 1.76 |
| total dysmenorrhea score at baseline 3/4 | -2.0 ± 1.48 |
| total dysmenorrhea score at baseline 5/6 | -3.2 ± 1.75 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DRSP 3 mg/EE 20 µg (13 Cycles) | — | 5/355 (1.4%) | 335/355 (94.4%) |
| DRSP 3 mg/EE 30 µg (6 Cycles) | — | 0/65 (0%) | 63/65 (96.9%) |
| Event | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| AppendicitisInfections and infestations | 1/355 | 0/65 |
| DysmenorrhoeaReproductive system and breast disorders | 1/355 | 0/65 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/355 | 0/65 |
| Facial palsyNervous system disorders | 1/355 | 0/65 |
| Enteritis infectiousInfections and infestations | 1/355 | 0/65 |
| Event | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) |
|---|---|---|
| HeadacheNervous system disorders | 215/355 | 39/65 |
| NasopharyngitisInfections and infestations | 182/355 | 34/65 |
| NauseaGastrointestinal disorders | 128/355 | 25/65 |
| DysmenorrhoeaReproductive system and breast disorders | 124/355 | 20/65 |
| MetrorrhagiaReproductive system and breast disorders | 97/355 | 9/65 |
| Genital haemorrhageReproductive system and breast disorders | 97/355 | 14/65 |
| Coagulation test abnormalInvestigations | 70/355 | 12/65 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 55/355 | 11/65 |
| Abdominal pain lowerGastrointestinal disorders | 53/355 | 5/65 |
| Plasminogen increasedInvestigations | 18/355 | 7/65 |
| Age Continuous(years) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Mean | 29.0 (20 to 44) | 30.9 (20 to 43) | 29.3 (20 to 44) |
| Sex: Female, Male(Participants) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Female | 349 | 65 | 414 |
| Male | 0 | 0 | 0 |
| Diagnosis type(participants) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Functional dysmenorrhea | 273 | 53 | 326 |
| Organic dysmenorrhea | 76 | 12 | 88 |
| Details of organic dysmenorrhea(participants) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Endometriosis | 24 | 4 | 28 |
| Uterine fibroids | 27 | 7 | 34 |
| Uterine adenomyosis | 35 | 8 | 43 |
| Endometrial polyp | 1 | 0 | 1 |
| Bicornuate uterus | 3 | 0 | 3 |
| Multiple endometrial polyp | 1 | 0 | 1 |
| Uterine enlargement | 1 | 0 | 1 |
| Average length of menstrual cycle(days) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Mean | 29.5 (25 to 38) | 29.5 (25 to 38) | 29.5 (25 to 38) |
| Body Mass Index(kg/m^2) | DRSP 3 mg/EE 20 µg (13 Cycles) | DRSP 3 mg/EE 30 µg (6 Cycles) | Total |
|---|---|---|---|
| Mean | 20.73 (16.2 to 29.9) | 20.56 (15.3 to 28.7) | 20.70 (15.3 to 29.9) |
The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Drospirenone